Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone Oncology"
DOI: 10.1016/j.jbo.2019.100222
Abstract: Background Chondrosarcomas are malignant cartilage-producing tumors showing mutations and changes in gene expression in metabolism related genes. In this study, we aimed to explore the metabolome and identify targetable metabolic vulnerabilities in chondrosarcoma. Methods A… read more here.
Keywords: chondrosarcoma; chondrosarcoma cell; inhibition; pathway ... See more keywords
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abo7219
Abstract: Compounds acting on multiple targets are critical to combating antimalarial drug resistance. Here, we report that the human “mammalian target of rapamycin” (mTOR) inhibitor sapanisertib has potent prophylactic liver stage activity, in vitro and in… read more here.
Keywords: sapanisertib; plasmodium kinases; plasmodium; activity ... See more keywords
Abstract A073: Using prebaseline and on-treatment tumor assessments to compare time to tumor size progression of hormonal therapy + sapanisertib vs an extrapolated hormonal therapy alone from a single-arm phase 2 study
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a073
Abstract: Introduction: This is a single-arm phase 2 trial testing the efficacy of the investigational dual TORC 1 and 2 inhibitor, sapanisertib (TAK-228), and hormonal therapy (HT) in estrogen receptor-positive patients relapsed or refractory to hormonal… read more here.
Keywords: progression; arm; sapanisertib; tumor ... See more keywords
Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.5569
Abstract: 5569 Background: Evidence suggests that activation of the PI3K/AKT/mTOR pathway by paclitaxel may play a role in the development of taxane resistance. Conversely, PI3K inhibitors have been shown to sensitize tumors to the effects of… read more here.
Keywords: mtor; combination; sapanisertib; serabelisib paclitaxel ... See more keywords